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Abstract
Hypoxia-inducible factor 1a (HIF-1a) is upregulated by hypoxia and oncogenic signalling in many
solid tumours. Its regulation and function in thyroid carcinomas are unknown. We evaluated the
regulation of HIF-1a and target gene expression in primary thyroid carcinomas and thyroid
carcinoma cell lines (BcPAP, WRO, FTC-133 and 8505c). HIF-1a was not detectable in normal
tissue but was expressed in thyroid carcinomas. Dedifferentiated anaplastic tumours (ATCs)
exhibited high levels of nuclear HIF-1a staining. The HIF-1 target glucose transporter 1 was
expressed to a similar level in all tumour types, whereas carbonic anhydrase-9 was signiﬁcantly
elevated in ATCs. In vitro studies revealed a functionally active HIF-1a pathway in thyroid cells
with transcriptional activation observed after graded hypoxia (1% O2, anoxia) or treatment with
a hypoxia mimetic cobalt chloride. High basal and hypoxia-induced expression of HIF-1a in
FTC-133 cells that harbour a phosphatase and tensin homologue (PTEN) mutation was reduced
by introduction of wild-type PTEN. Similarly, pharmacological inhibition of the phosphoinositide
3-kinase (PI3K) pathway using LY294002 inhibited HIF-1a and HIF-1a targets in all cell lines,
including those with B-RAF mutations (BcPAP and 8505c). In contrast, the effects of inhibition of
the RAF/MEK/extracellular signal-regulated kinase pathway were restricted by environmental
condition and B-RAF mutation status. HIF-1 is functionally expressed in thyroid carcinomas and
is regulated not only by hypoxia but also via growth factor signalling pathways and, in particular,
the PI3K pathway. Given the strong association of HIF-1a with an aggressive disease phenotype
and therapeutic resistance, this pathway may be an attractive target for improved therapy in
thyroid carcinomas.
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Introduction
Thyroid cancers represent the most common malig-
nancy of endocrine organs and their incidence is
increasing (Kondo et al. 2006). The precise molecular
mechanisms promoting the development and pro-
gression of the disease are only partially known.
Availabledatasuggestthatthemostfrequentmutational
events in these carcinomas are mutations in B-RAF,
leading to activation of the RAF/MEK (mitogen-
activated protein/extracellular signal-regulated kinase
(ERK) kinase)/ERK pathway and in phosphoinositide
3-kinase (PI3K)/AKT signalling (Kimura et al. 2003,
Houetal.2007).Arecentsummarysuggeststhatwhilst
B-RAF mutations represent an early stage event,
particularly in the development of papillary thyroid
carcinomas, changes in the PI3K pathway occur later
and are associated with aggressive transition (Paes &
Ringel2008).Todate,therehasbeennocomprehensive
analysis of the potential role of signalling mediated
via hypoxia-induced transcription cascades.
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response, which impacts on the activation of many
genes involved in the physiological adaptation of
tumour cells. This promotes tumour cell survival and
disease progression. Examples of such target genes
include the glucose transporter 1 (GLUT1), which
increases glucose uptake into cells for anaerobic
respiration (glycolysis), genes involved in the mainten-
ance of the intracellular milieu, for example, carbonic
anhydrase-9 (CA-9), MCT-4 and NHE-1/-6, and
genes that increase or restore vascular supply to the
cellssuchasvascularendothelialgrowthfactor(VEGF;
Pouyssegur et al. 2006). These adaptive processes are
controlled by hypoxia-inducible factor 1 (HIF-1),
which is composed of two subunits, the oxygen-
sensitive HIF-1a and the constitutively expressed
HIF-1b. Under normoxic conditions, HIF-1a is rapidly
inactivatedthroughhydroxylation, which enablesbind-
ing of the molecule to von Hippel–Lindau protein.
Subsequently, the complex is degraded in the protea-
some via the ubiquitination pathway (Pouyssegur et al.
2006). In hypoxia, HIF-1a is stabilized, translocates to
the nucleus and, following heterodimerization with
HIF-1b and cofactors like CREB-binding protein
(CBP)/p300, activates HIF-responsive genes.
Hypoxia is a characteristic hallmark of aggressive
malignancies, and HIF-1a signalling is upregulated in
many tumours. It is important to note that HIF-1a
signalling is activated not only by lowered oxygen
tension within the tumour but also by oncogenic
stimulation through aberrant growth factors or through
the loss of tumour suppressor gene activity, e.g.
phosphatase and tensin homologue deleted on chromo-
some ten (PTEN), and studies have implicated both
the MEK/ERK and PI3K pathways in HIF-1 regulation
(Bardos & Ashcroft 2005, Shafee et al. 2009). Both
stimuli induce cellular adaptation to an anaerobic state
andsubstantiallychangecellphysiology(Garcia2006).
HIF-1a-dependent activation of target genes has major
implications on tumour aggressiveness and local or
distant invasiveness. In addition, HIF-1a may reduce
the effectiveness of cancer treatment because it has
been shown to play a role in therapeutic resistance to
radiotherapy and some forms of chemotherapy (Unruh
et al. 2003, Williams et al. 2005, Brown et al. 2006,
Chicheetal.2009).Asradioiodinetreatmentorexternal
beam radiation is a ﬁrst line non-surgical therapy in
disseminated differentiated or undifferentiated thyroid
tumours, the effect on radiation resistance is of high
therapeutic relevance in these aggressive carcinomas.
Previous data characterizing the potential role of
HIF-1ainthyroidcarcinomasarelimited.Invitrostudies
have shown that stimulation of VEGF production in
SW579thyroidtumourcellsisdependentonHIF-1aand
AP-1(Poulakietal.20 03 ).Inaclinicalstudy,lowlevels
of HIF-1a mRNA were observed in thyroid carci-
nomas using a microarray approach (Jubb et al.2 0 0 4 ).
However, expression of HIF-1 target genes like
GLUT1 (Yasuda et al. 2005) and VEGF (Tuttle et al.
2002) was observed and appeared to be related to
tumour pathological grade/type.
Currently, little is known about the hypoxic
regulation of HIF-1a and the potential interaction with
oncogenic pathways in thyroid carcinomas. Thus, the
aim of the present study was to determine whether
HIF-1a and its target genes, CA-9 and GLUT1, are
expressed in primary tumours and cell lines derived
from thyroid carcinomas. The cell line panel included
thosederivedfrompapillary(BcPAP),follicular(WRO
and FTC-133) and anaplastic (8505c) thyroid tumours.
They reﬂected the common genotype aberrations
associated with these subtypes with the highly
prevalent B-RAF V600E mutation present in the
BCPAP and 8505c cell lines (Xu et al. 2003, Elisei
et al. 2008), and the FTC-133 harbouring a PTEN
mutation (Weng et al. 2001).
To elucidate functional HIF-1a regulation, we
exposed thyroid cancer cell lines to graded hypoxia
or stimulation by a biochemical hypoxia mimetic
cobalt chloride (CoCl2) and tested the impact of
inhibitors on the relevant genetically altered pathways
in these cells. We show that HIF-1a is expressed in
both differentiated and dedifferentiated primary
thyroid carcinomas as well as in thyroid cancer cell
lines. HIF-1a protein levels and reporter gene activity
are upregulated by lowering the oxygen tension and by
chemical stimulation, paralleled by increased levels of
the HIF-1a target genes, CA-9 and GLUT1. Basal and
induced expression of HIF-1a in FTC-133 cells
bearing a PTEN mutation is high. Transfection of
wild-type PTEN (WTPTEN) as well as silencing the
PI3K/AKT pathway via pharmacological inhibition
decreased both HIF-1a and target gene expression.
This supports an important link between PI3K/AKT
and HIF-1a, which may have particular relevance to
disease progression in thyroid carcinomas.
Materials and methods
Patients and cell lines
Thyroid tissues obtained from patients undergoing
surgery for thyroid carcinomas (12 dedifferentiated ana-
plastictumours(ATC)and25differentiatedcarcinomas,
13 follicular (FTC) and 12 papillary (PTC) carcinomas)
weresnapfrozeninliquidnitrogenandstoredatK80 8C.
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were performed at the Department of Pathology of
the Medical School of Hannover and of Halle
University. We compared these results with 13 normal
thyroid tissues obtained during surgery from patients
with parathyroid adenomas. All patients involved in
this study gave informed consent, and the use of the
material was approved by the respective Ethical
Committees. Snap frozen tissue was parafﬁn embedded
and stained by standard immunohistochemistry
techniques.
For functional studies, we used thyroid carcinoma
cell lines derived from papillary (BcPAP), follicular
(WRO and FTC-133) and anaplastic thyroid carci-
nomas (8505c) (Schweppe et al. 2008). WRO, BcPAP
and 8505c were cultured in RPMI supplemented with
2 mM glutamine (Gibco; Invitrogen Ltd) and 10%
(v/v) FCS (Biosera, East Sussex, UK). The parental
FTC-133 cells were cultured in DMEM/HAM’S F-12
with 2 mM glutamine and 10% FCS (v/v) (PAA
Laboratories GmbH, Haidmanweg, Austria). Medium
for the stably transfected FTC-133 PTEN and PCI
NEO derivatives was supplemented with 1.44 mM
G418. Additionally, we transfected normal thyroid
cells with SV40 to obtain stable cell lines as previously
described (Belge et al. 1995), as a model for normal
thyroid function.
Experimental protocol for hypoxia/anoxia
Exposures to anoxia were undertaken by placing cells
in an anaerobic chamber (Bactron anaerobic chamber,
Sheldon Manufacturing, Cornelius, OR, USA) in
which a gas mixture of 5% CO2:5% H2:90% N2 is
passed over a palladium catalyst to remove residual
oxygen. Other oxygen environments were generated by
continuous gassing of sealed chambers containing cell
cultures with gas mixtures containing the appropriate
oxygen tension with 5% CO2 and N2 balance. As an
alternative, cells were treated with the CoCl2 (100 mM;
Sigma) for 18 h. To modulate PI3K or ERK pathways,
the cells were treated for 18 h with 50 mM LY294002
or 50 mM PD98059 respectively (Sigma–Aldrich).
Primary antibodies
The following antibodies were used: mouse mono-
clonal anti-HIF-1a (BD Transduction Laboratories,
Oxford, UK), rabbit polyclonal anti-von Willebrand
Factor (vWF; DAKO, Ely, UK), rabbit polyclonal anti-
GLUT1 (Chemicon (Millipore), Temecula, CA, USA),
monoclonal anti-CA-9 (kindly provided by Dr Jaromir
Pastorek, Bratislava, Slovakia), mouse monoclonal
anti-b-actin (Sigma).
Western blot analysis
Cells were lysed in 100 ml lysis buffer (10 mM Tris
(pH 7.4), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA,
50 mM NaF, 1 mM sodium orthovanadate, 1% Triton
X-100 v/v, 0.5% Nonidet P-40 v/v, 2 mM leupeptin,
0.15 mM aprotinin, 1.46 mM pepstatin, 1 mM
phenylmethansulfonyl ﬂuoride). For western blot
analysis, proteins (20 mg/lane) were resolved on a
7.5% SDS-PAGE gel and electrotransferred onto a
polyvinylidene ﬂuoride (PVDF) membrane (Millipore,
Schwalbach, Germany) using standard procedures.
After blocking with 5% non-fat dry milk w/v in
PBS-T (137 mM NaCl, 2.7 mM KCl, 4.3 mM
di-sodiumhydrogenphosphate, 1.4 mM potassium-
di-hydrogenphosphate, 0.1% Tween20 v/v) overnight
at 4 8C, the blot was probed with primary antibodies.
The blot was then reacted with suitable secondary
alkaline phosphatase-conjugated antibodies (Dianova,
Hamburg, Germany), followed by detection of the
protein with CDP-Star chemiluminescent reagent
(Applied Biosystems, Foster City, CA, USA). Finally,
the blot was stripped and reprobed for b-actin to ensure
equal loading and transfer of proteins.
Immunohistochemistry
Sections (3 mm thick) of parafﬁn-embedded normal
thyroid, FTC, PTC and ATC tissues were dewaxed,
rehydrated and subjected to antigen retrieval in citrate
buffer (pH 6.0) or Tris–EDTA buffer (pH 8.5) in a PT
module (Lab Vision, Suffolk, UK) for 30 min at 98 8C.
Theslides were incubatedfor1 hinPBSwith 10%goat
or rabbit serum to block non-speciﬁc antibody binding
followed by 1-h incubation with the primary antibody
(seeabove). Afterwashing,thesectionswere incubated
with a suitable biotinylated secondary antibody (1:300
dilution) for 1 h. Antigen–antibody complexes were
visualized by applying a standard streptavidin–biotin
complex (Vector Laboratories, Peterborough, UK)
for 35 min followed by 3,3-diaminobenzidine (DAB)
(Sigma) for 6–8 min. Sections were counterstained
with haematoxylin. Control sections were incubated
with rabbit or mouse IgG as the primary antibody.
The extent of immunostaining was evaluated by the
method described by Allred et al. (1993). The mean
scores of three independent reviewers are shown.
Immunoﬂuoresence and cell imaging
Cells were seeded at a density of 5!10
3 cells/well
in a 96-microplate ‘CytoWell’ (Nunc, Wiesbaden,
Germany). Cells were ﬁxed in 4% paraformaldehyde
v/v in PBS for 10 min and permeabilized in 0.1%
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containing 3% BSA w/v in PBS for 30 min. Incu-
bations with primary antibodies were followed by
FITC-conjugated secondary antibody (Dianova) for1 h
at 37 8C. Finally, cells were embedded in ProLong
Gold Antifade Reagent with DAPI (Invitrogen) and
viewed by ﬂuorescent microscopy (DeltaVision,
Washington, DC, USA). Immunoﬂuorescence images
were acquired with an Olympus BX71 microscope.
Assessment of HIF-1 proﬁciency
Cells were infected with an adenovirus containing a
ﬁreﬂy luciferase reporter construct linked to trimers of
the lactate dehydrogenase (LDH) hypoxia-responsive
element (HRE) sequence (Cowen et al. 2004) 5 h prior
toexposuretotherespectivecondition.Themultiplicity
of infection (MOI; number of viral particles per cell)
used was 20. Cells were then trypsinized and plated in
triplicateina96-wellplate.Cellsreceivedeither50 mM
LY294002 or 50 mM PD98059, or no treatment and
were subjected to normoxia, 1% hypoxia, anoxia or
100 mM CoCl2 for 18 h. Cells were then harvested and
luciferase activity was analysed using a manufactured
kit (Promega UK Ltd) following the recommended
guidelines. A MicroLumat LB 96 luminometer (EG &
G Berthold Technologies, Harpenden, UK) was used to
measure luminescence. The efﬁciency of adenoviral
infection was tested by infecting cells with an
adenovirus expressing green ﬂuorescent protein (GFP)
under the control of a constitutively active viral
promotor (cytomegalovirus (CMV)); a kind gift from
Dr Nasreen Akhtar, Manchester, UK.
Silencing of HIF-1a
Cells were transfected with 100 nM HIF-1a siRNA
(50-AGGTGGATATGTCTGGGTTtt-30) (Dharmacon
Research, Inc., Surrey, UK) and control siRNA (Santa
Cruz Biotech Inc, Santa Cruz, CA, USA) for 4 h and
were then exposed to 1% hypoxia, anoxia or normoxia
for 18 or 24 h. Cells lysates were collected and western
blotting was performed, as previously described.
Vascular endothelial growth factor ELISA
Cells were incubated in normoxia or anoxia for 18 h,
and the media was removed for the analysis of VEGF
levels. Cells were harvested and the protein concen-
tration was determined as previously described
(Williams et al. 2005). The concentration of secreted
VEGF was determined using a Duoset Human VEGF
ELISA kit (R&D Systems, Abingdon, UK) according
to the manufacturer’s instructions.
Statistical analysis
For analysis between the various stimulation con-
ditions, the paired t-test and a one-way ANOVA with
post test Tukey were used.
Results
HIF-1a protein is expressed in differentiated and
dedifferentiated thyroid tumours but absent from
normal thyroid tissue
The expression of the HIF-1a protein was ﬁrst studied
in snap frozen normal thyroid and differentiated and
dedifferentiated primary thyroid carcinomas. Normal
thyroid tissue did not show HIF-1a immunostaining,
whereas 11 out of 12 dedifferentiated ATCs studied
showed strong HIF-1a staining. In contrast, differ-
entiated PTCs and FTCs showed variable distribution
and intensityof staining for HIF-1a (Fig. 1A).This was
supported by a semiquantitative evaluation of HIF-1a
expression in these tumours (Fig. 1B). Within the
tumour, the staining pattern varied between differ-
entiated and dedifferentiated tissue. Positive staining
was diffusely distributed in ATCs compared with
PTCs and FTCs where HIF-1a expression varied
considerably from very intense, localized staining to
almost no staining. HIF-1a expression was signi-
ﬁcantly greater in all tumour types than in normal
tissue and ATC and FTC tumours showed the highest
levels of expression (Fig. 1B).
To characterize the possible relationship between O2
diffusion-dependent hypoxia and HIF-1a expression,
we evaluated microvascular density in these tumours
usingvWFstainingandcomparedthepatterntoHIF-1a
(Fig. 1C). No clear relationship between both markers
wasdetectable.Inaddition,weevaluatedtheexpression
of the HIF target genes, CA-9 and GLUT1 (Fig. 1C),
which can reﬂect tissue hypoxia in other epithelial
tumours (Airley et al. 2003). GLUT1 was expressed to
equivalent levels in all analysed tumours (Fig. 1C and
D). CA-9 was expressed in all dedifferentiated ATC
tumourscomparedwith77%ofFTCsand80%ofPTCs.
In addition to increased frequency of expression, the
level of CA-9 observed was signiﬁcantly higher in
ATCs compared with PTC and FTC tumours (Fig. 1D).
Thyroid cell lines grown in culture show a
functional HIF-1 response to hypoxia and
hypoxic mimetics
To further investigate the functional regulation of
HIF-1a, we examined cell lines derived from normal
thyroid tissue and from PTC (BcPAP), FTC (WRO and
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thyroid origin are not immortal. Therefore, to assess
HIF-1a response in a genetically normal environment,
cells were transfected with SV40 to create an immortal
cell line from normal thyroid tissue. Consistent with
the immunohistochemical studies of clinical material,
the normalthyroid-derived cellshad undetectable basal
levels of HIF-1a (Fig. 2A). Exposure to the hypoxic
mimetic CoCl2 induced both HIF-1a expression and
that of the downstream targets, CA-9 and GLUT1.
In the thyroid carcinoma cells, the expression of
HIF-1a increased with severity of hypoxia, with anoxia
inducing a higher level of expression than hypoxia
(1% oxygen) in all cell lines. The FTC-133 cell line
exhibited the highest levels of HIF-1a expression of
the thyroid carcinoma cell line panel used (Fig. 2B).
CA-9 and GLUT1 were detected at various levels in all
cells exposed to reduced oxygen (Fig. 2B). Whereas
basal HIF-1a and CA-9 expression was markedly
lower than the induced states for all cell lines, for
GLUT1 the relative change in expression was
considerably lower (Figs 3C and 4C). The secretion
of VEGF was also monitored in response to anoxia.
Basal VEGF levels varied across the cell line panel,
with the FTC derivatives showing the highest
expression. In all cell lines, VEGF expression was
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Figure 1 HIF-1a protein is expressed in primary thyroid tumours and can be associated with CA-9 and/or GLUT1 expression but not
vWF. (A) Immunohistochemical staining for HIF-1a (brown staining) in primary thyroid carcinomas and normal thyroid tissue. Five
examples of normal thyroid, papillary (PTC), follicular (FTC), and anaplastic (ATC) carcinomas are displayed, which show the
variation of HIF-1a expression from the lowest (left) to highest (right) expression observed in each subtype. (B) Semiquantitative
analysis of HIF-1a immunostaining performed according to Allred et al. (1993). Total scoring is derived from the intensity and
proportion plots. Data represent the meanGS.E.M. of three independent scorers. (C) Representative immunohistochemical staining
for HIF-1a, vWF, CA-9 and GLUT1 (each staining brown) in papillary, follicular and anaplastic thyroid carcinomas (D)
Semiquantitative analysis of CA-9 and GLUT1 expression showing total scoring only. The proportion of tumours showing positive
staining is given below the ﬁgures. The signiﬁcance value given on the CA-9 plot is versus PTC and FTC.
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(Fig. 2C). Consistent with the western blotting data,
immunoﬂuorescence studies revealed low cyto-
plasmic expression of HIF-1a in normoxic conditions.
Hypoxia/anoxia HIF-1a expression was induced and
was nuclear localized (data not shown).
Oncogenic signalling via PI3K impacts on HIF-1a
activity and expression in thyroid cells
Activating mutations within the RAF/MEK/ERK and
PI3K pathways have been associated with oncogenic
transformation in thyroid cancer. Similarly both
pathways have been implicated in the regulation of
HIF-1. To undertake a quantitative assessment of the
impact of inhibition of both pathways upon HIF
function, we employed an adenoviral-based HIF-1a
reporter gene assay. Atrimerof the HRE from the LDH
gene was linked to the ﬁreﬂy luciferase gene and
cloned into an E1/E3-deleted adenoviral backbone. We
have previously shown that luciferase expression
driven by this construct is robustly upregulated in
response to hypoxia in a range of cell lines (Cowen
et al. 2004, Chadderton et al. 2005). The MOI used was
20 viral particles per cell, which was sufﬁcient for
infection of O80% of the cell population as
ascertained using an adenovirus encoding GFP (data
not shown). When WRO, BcPAP and 8505c cells were
infected with the HRE luciferase virus, graded
hypoxia/anoxia-induced HIF-1a reporter gene activity
in all cell lines (Fig. 3A). The highest level of
expression was observed in the anaplastic 8505c cells
in all conditions. Interestingly, neither BcPAP nor
WRO cells showed induction following treatment with
CoCl2. We next investigated the impact of inhibiting
PI3K or MEK activity under the different environ-
mental conditions by exposing the cells to 50 mM
LY294002 or 50 mM PD98059 respectively. Treatment
with LY294002 reduced basal (normoxic) reporter
expression in WRO and 8505c cells, whilst having no
effect in BcPAP. PD98059 had no effect in any cell
type. Following CoCl2 exposure, the induction
observed in 8505c cells was signiﬁcantly reduced by
both LY294002 and PD98059. Under hypoxic/anoxic
conditions, LY294002 treatment signiﬁcantly reduced
the expression in all cell lines. In contrast, the effect of
PD98059 appeared oxygen and cell line dependent,
with inhibitory effects observed only in BcPAP and
8505c under 1% oxygen, and no effects seen in any cell
line under anoxia (Fig. 3B). The ‘targeted’ effects of
PD98059 against BcPAP and 8505c cells are perhaps
in keeping with the mutational status of BRAF in
these cells.
Western blotting for HIF-1a, CA-9 and GLUT1 was
also undertaken in the LY294002- and PD98059-
treated cells (Fig. 3C). In general, the level of HIF-1a
expression following hypoxia/anoxia or CoCl2 (where
apparent) was reduced in the presence of LY294002.
Coincident with this was a reduction in CA-9
expression. GLUT1 appeared reduced only on 8505c
cells (Fig. 3C). Interestingly, the signiﬁcant decreases
in reporter gene expression observed for 8505c cells
following CoCl2 or hypoxic (1%) exposure in the
presence of PD98059 were not related to changes
in HIF-1a expression (Fig. 3B and C). In contrast,
previous studies undertaken with the B-RAF-mutated
putative thyroid line NPA demonstrated a clear
correlation between the inhibition of reporter activity
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Figure 2 HIF-1a and downstream target expression are
upregulated in response to hypoxia and hypoxia mimetics in
immortalized normal thyroid tissue (A) and cell lines derived
from papillary (BcPAP), follicular (WRO and FTC-133) and
anaplastic (8505c) thyroid carcinomas (B and C). Normal
thyroid cells immortalized using SV40 (according to Belge et al.
(1995)), or thyroid cell lines were exposed to hypoxia
(1% oxygen), anoxia or CoCl2 (100 mM) for 18 h. Cells were
harvested and lysed samples containing 20 mg protein were
subjected to western blotting (A and B) using primaryantibodies
against HIF-1a, CA-9 and GLUT1 with b-actin used as a loading
control (see Materials and methods for details). Blots are
representative of four independent experiments. For the
determination of VEGF, media samples were removed from the
cells after 18 h of exposure to condition and the level of VEGF
determined by commercial ELISA, corrected to the amount of
protein within the cell cultures from which the medium was
taken. Data represents the meanGS.D. of four independent
experiments. Signiﬁcance values relate to comparisons
between condition and normoxic concentrations of VEGF for
each cell type.
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(data not shown). These cells have now been identiﬁed
as originating from melanoma (Schweppe et al. 2008)
where the MAPK pathway has been clearly shown to
regulate HIF activity (Kumar et al. 2007).
Genetic restoration of PTEN reduces HIF-1
expression, activity and sensitivity to
pharmacological inhibition of the PI3K
and MEK pathways
These data strongly implicated PI3K pathway acti-
vation in the regulation of HIF-1 and downstream
target expression in thyroid cell lines, including those
with known B-RAF mutation. To further investigate
the role of PI3K, we utilized the FTC-133 model with
known PTEN mutation. Consistent with the lack of
PTEN, HIF-1a expression is higher in this cell line
than the rest of the panel (Fig. 2B). Further basal
activation of the luciferase reporter gene in these cells
is higher than that observed in BcPAP, WRO and
8505c cells (compare Figs 3 and 4A). This is not due to
differences in adenoviral infection efﬁciency, which is
similaracrossallcellsattheMOIused(datanotshown).
Introduction of wild-type (WT) PTEN into the
FTC-133 cells reduced the basal expression of the
HRE reporter gene and the level of activity observed in
the hypoxic conditions used. Cells expressing the
empty vector PCI NEO construct behaved as the
parental WT cells (Fig. 4A). Basal reporter expression
was reduced by LY294002 in WT and PCI NEO cells,
although this did not achieve signiﬁcance. In hypoxia,
signiﬁcant reductions were restricted to WT and PCI
NEO cells, whilst in anoxia LY294002’s inhibitory
effects were apparent in all cells. Interestingly, in
CoCl2 and hypoxic/anoxic conditions, treatment with
PD98059 resulted in signiﬁcant reduction in HIF-1
reporter expression in WT and PCI NEO cells, whilst
having no signiﬁcant effect in the PTEN-expressing
cells (Fig. 4B). Consistent with the reporter gene
activity assays, HIF-1a expression was reduced in the
PTEN-expressing FTC-133 cells compared with PCI
NEO-expressing controls (Fig. 4C). In keeping with
the ﬁndings in the other thyroid cell lines, LY294002
reduced both HIF-1a and CA-9 protein expression,
whilst having minimal effects on GLUT1and PD98059
had little effect on any of the proteins analysed via
western blot (Fig. 4C).
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Given the clear differences in response of HIF-1a and
its target genes (CA-9 and GLUT1), in response to the
PI3K inhibitor, we hypothesize that there is a direct
modulation of HIF-1a and particularly its target gene
CA-9, by the PI3K pathway. To elucidate the HIF-1a-
speciﬁc effect, we silenced HIF-1a by treating cells
over 18–24 h with HIF-1a siRNA. Where signiﬁcant
knockdown of HIF-1a protein expression was
observed, this was co-incident with a reduction in
CA-9 expression (Fig. 5). The results clearly demon-
strate that there is HIF-1a-dependent regulation of
CA-9 in thyroid cell lines representative of each
histological subtype (Fig. 5).
Discussion
Despite thyroid carcinomas being the most common
endocrine tumour, the mechanisms involved in disease
progression are still poorly understood. Here we report
a potential role for HIF-1a that appears to be a key
target of the oncogenic signalling pathways associated
with advancing tumour grade. HIF-1a protein was
expressed in primary thyroid carcinomas but absent
from normal thyroid tissue. Consistent with previous
studies, the level of HIF-1a protein expression was
highest in the aggressive dedifferentiated, anaplastic
thyroid tumours. The distribution of HIF-1a was
diffuse in these tumours, which may suggest regulation
of the protein via a combination of tumour genotype
and microenvironment. In contrast, differentiated
papillary and follicular tumours commonly showed
focal expression, which is perhaps consistent with the
presence of diffusion-limited chronic hypoxia.
However, analysis of tumour vasculature using vWF
was unable to reveal an association between HIF-1a
expression and the vessel distribution. Two down-
stream targets of HIF-1 were also assessed; CA-9 and
GLUT1. On the one hand, GLUT1 was expressed to
similar levels in all thyroid cancers analysed. On the
other hand, CA-9 was detected in 100% of ATC
samples, but only in around 80% of FTC and PTCs.
In addition, the level of CA-9 expression varied
between cancer subtypes, with signiﬁcantly elevated
levels detected in the dedifferentiated ATCs.
This suggests that the expression of CA-9 may be
associated with a more aggressive disease phenotype in
thyroid carcinoma.
Our data raises the question of whether HIF-1a
expression (especially in dedifferentiated thyroid
carcinomas) is a) of pathophysiological relevance
and b) relates to an adaptation to hypoxia-induced
invasion and proliferation. The detection of high
levels of HIF-1a target genes in dedifferentiated
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agrees with previous work describing high expression
levels of CA-9 in anaplastic thyroid carcinomas (Jubb
et al. 2004).
The regulation of GLUT1 expression by HIF-1a is
also of great interest. This is because overexpression of
GLUT1 has been described in thyroid cancers and is
linked to tumour aggressiveness. However, the
underlying mechanism is not clearly understood
(Schonberger et al. 2002, Kim et al. 2006). Recent
data (Yasuda et al. 2005) suggest almost 50% of
differentiated thyroid tumours express GLUT1 with
expression not always being restricted to the mem-
brane. Standard immunohistochemical techniques as
used in our study would not allow us to clearly
differentiate membranous from cytoplasmic immuno-
staining. However, our data suggests that differentiated
tumours express GLUT1 predominantly in the
cytoplasm, in contrast to a predominant membranous
staining in dedifferentated carcinomas suggesting the
presence of a functionally active transporter.
From our studies with clinical material, we were
restricted to making correlative observations between
HIF-1a and target protein expressions. To substantiate
our observations, we undertook a number offunctional
studies in thyroid carcinoma cell lines and in
immortalized cells derived from normal thyroid tissue.
Under non-stimulated conditions, HIF-1a (where
detected) was predominantly localized in the cyto-
plasm, but underwent stabilization with lowering
oxygen tension or treatment with the hypoxic mimetic
CoCl2 and translocates to the nucleus (data not shown).
HIF-1a expression was not observed in immortalized
normal thyroid cells, but was markedly induced by
CoCl2. This treatment also resulted in induction of
CA-9 and GLUT1. This shows that normal thyroid
(1, no treatment; 2, control siRNA; 3, HIF-1α siRNA)
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Figure 5 Genetic silencing of HIF-1a reduces CA-9 expression in thyroid carcinoma cell lines. Cells were transfected with 100 nM
HIF-1a siRNA (lanes 3) or control siRNA (lanes 2) for 4 h before exposure to normoxia (left panel, lane 1 untreated control), 1%
hypoxia or anoxia for 18 or 24 h. Cells lysates were collected, and western blotting was performed as previously described for
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response to hypoxia and suggests that in the clinical
samples, the lack of HIF-1a expression was due to a
lack of micro-environmental or genetic stimulus.
The thyroid carcinoma cells also showed a
functional HIF-1 response as a consequence of
hypoxia, identiﬁed both from protein expression and
HIF reporter activation studies. These observations are
consistent with data from other epithelial tumours
(Pouyssegur et al. 2006). Interestingly, of the two
downstream targets analysed, CA-9 appeared more
responsive than GLUT1 to stimulation via HIF-1 and
was markedly induced in all cell lines. The level of
induction of GLUT1 was much lower, and the
modiﬁcation of GLUT1 expression following treat-
ments that ablated HIF-1a expression was less
convincing. The highest levels of HIF-1a activity
were apparent in the anaplastic cell line 8505c and the
follicular cell line FTC-133. These harbour classic
mutations in B-RAF and PTEN respectively leading to
activation of oncogenic pathways, which have been
reported to inﬂuence HIF-1 activity (Ba ´rdos &
Ashcroft 2005), and are known to associate with
aggressive disease. B-RAF mutations are known to
alter the biological status of cancer cells, promoting
tumour progression in a range of cancers. Animal
models support a high proliferation rate of B-RAF-
mutated versus non-B-RAF-mutated thyroid carci-
noma cells. BRAF mutations leading to activation of
the MAPK/ERK signalling pathway are the most
important mutational event in thyroid carcinomas,
especially in PTC progression (Durante et al. 2007,
Lee et al. 2007, Elisei et al. 2008).
To study the impact of oncogenic signalling on HIF-
1a expression and activity, we used pharmacological
inhibitorsofthePI3K(LY294002)andRAF/MEK/ERK
pathway (PD98059). Reporter gene expression assays
revealed that PD98059 could inhibit HIF-1 activity in
cell lines with B-RAF mutation (8505c), although this
was not seen in anoxia. Interestingly, HIF-1 activity
was also inhibited by PD98059 in FTC-133 cells but
not the additional FTC cell line WRO. In contrast,
inhibition of the PI3K pathway using LY294002
inhibited HIF activity in all cells lines. Reintroduction
of PTEN into the FTC-133 line reduced HIF-1 activity
and rendered it less susceptible to inhibition via
pharmacological manipulation of either the PI3K or
RAF/MEK/ERK pathways.
Although PD98059 had some negative effects on
HIF activation in the reporter assays, this was not
translated into changes in HIF-1a nor downstream
target protein expression. The much more substantial
changes in reporter activity as a consequence of
LY294002 treatment were, however, reﬂected in
reduced expression of both HIF-1a and CA-9.
LY294002-mediated effects on GLUT1 appeared both
cell line and condition dependent. The differences
between reporter and western data potentially reﬂect
the relative sensitivity of the two assays. Furthermore,
as suggested by the GLUT1 and CA-9 data, different
HIF targets respond in subtly different ways and the
reporter assay is based on the regulation of the LDH
gene. OurdatasuggeststhatHIF-1aisnotonlyhypoxia
regulated but also directly modulated by the PI3K
pathway, even in cells where one may have anticipated
a predominant role for the RAF/MEK/ERK pathway.
A recent systematic analysis suggests that 15% of
PTC and w50% of FTC have a mutation in the
PI3K/AKT signalling pathway (Hou et al. 2007),
which has been linked to tumour aggressiveness
(Paes & Ringel 2008). Our data showed that the PI3K
inhibitor, LY294002, very distinctly decreased both
HIF-1a and CA-9 indicating a pronounced reliance of
the expression of both proteins upon PI3K signalling.
Recent evidence highlights the importance of this
interaction on tumour progression, as it has been
shownthatdownregulationofCAsdramaticallyreduces
tumour cell proliferation (Chiche et al. 2009). Here we
have shown that HIF-1a silencing by siRNA contribute
signiﬁcantly but not exclusively to the downregulation
of CA-9 with additional independent inhibitory effects
ofPI3KinhibitorsonCA-9butnotGLUT1.Therelative
weak inhibition seen may be explained by the reported
long half-live of CA-9 (48 h) and an even longer one
of GLUT1 (Heilig et al. 2003, Sobhanifar et al. 2005,
Vordermark et al. 2005). This close link between one
of the most frequently altered signalling cascades in
thyroid carcinomas, PI3K, and HIF-1a further supports
an important integrative role of PI3K and HIF-1a in the
adaptation and survival of tumour cells. This ﬁts well
into the concept of the PI3K pathway being involved in
the aggressive behaviour of these cells (Paes & Ringel
2008) and may have important implications in the
therapeutic treatment of thyroid tumours. Recent
literature supports an impact of small therapeutic
molecules that modulate HIF-1a expression in the
sensitivity to chemotherapy and more importantly for
thyroid tumours, to radiotherapy (Moeller & Dewhirst
2004). Blocking HIF-1a, especially in dedifferentiated
thyroidcarcinomas,mayincreasesensitivitytoionizing
radiationandthusopensnewtherapeuticoptionsforthe
disease (Bardos & Ashcroft 2005). As an obvious next
step, these effects would require further testing in vivo
to evaluate whether the data offer hope for improving
the therapeutic outcome of thyroid carcinomas associ-
ated with poor prognosis.
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carcinomas and is regulated not only by hypoxia but
also via alteration of growth factor signalling pathways
and, in particular, the PI3K pathway. HIF-1a
expression appears to be in part responsible for the
regulation of CA-9 and GLUT1 in the disease.With the
known desensitizing effects of HIF on radiation and
chemotherapy, HIF-1a may represent an important
target for the treatment of thyroid carcinomas.
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